New York – Paris
Eric M. Attias
“Sharing our partners successful experience and complementary expertise leads to increased value creation for our startups.”
In 2014, Eric M. Attias launched Forepont Capital Partners in New York. Eric sourced and invested in five high performing medical ventures including San Diego-based decacorn SAMUMED, UK based biotech company SiSaf and French start-up BioSpeedia.
Since 2013, through his work in funding medical research and as chairman of the Neurogen Research Foundation, Eric developed partnerships and strong ties with CEOs and top management of some of the biggest pharmaceutical companies, renowned hospitals and dozens of leading researchers and KOLs in Neurology.
Prior to Forepont, he co-founded Nexar Capital Group, in 2009, backed by New York private equity firm Aquiline.
Nexar capital acquired both AAAM, Alternative Asset Management business of insurance group Allianz and Ermitage Group from London based private equity firm Caledonia Partners.
After restructuring and integrating both businesses, Nexar controlled over $4 billion of Assets by its 2nd anniversary. Nexar was then acquired by Swiss banking group UBP in 2012.
In 2002, Eric established Sociétée Generale Asset Management business in New York. In four years, he built SGAM Inc into a $200 million annual revenue business with a staff of 60 and over $10 billion of assets under management.
In 1999, in addition to his role in the Investment bank of DrKW (Wasserstein, Perella & Co) in New York, Eric was put in charge of its strategic venture fund DrKW OV Ltd. He managed the $50-million fintech ventures fund, sourced and seeded blockbusters like CapitalIQ and Creditex.
Eric started his career, in the late 80’s, as an OS engineer for Apple after a thesis in neural networks and genetic algorithms.
Eric is a recipient of the Rothschild GE Fellowship for advanced study and postgraduate research in applied mathematics & data science. He received the Bishofsheim Scholarship in mathematics. Eric also holds an MBA in finance from Columbia University.
Dr Ismail Kola
“The opportunity to help Forepont and its uniquely creative ecosystem of companies really captured my imagination. Mentoring a new generation of science entrepreneurs will add to the pleasure of the challenge”.
Ismail Kola joined Forepont in early 2019 as a General Partner in charge of all scientific decisions.
He has led investments into biotech companies such as GPN Vaccines and Mobius BioMedical where he contributes his scientific expertise and his broad network as a board member and a scientific advisor to the firms.
Prior to Forepont, Ismail held several senior executive positions in the pharmaceutical industry as he has published 159 papers in top scientific journals which have been cited over 15,000 times and has brought 17 major medicines to market during his 20 year career in the pharmaceutical industry.
Ismail Kola was until 2018 the Chief Scientific Officer of UCB, the Belgium leading pharmaceutical company. He joined UCB from Schering Plough Corporation where he was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation, and Chief Scientific Officer, Schering Plough Corporation.
Ismail came to Schering-Plough from Merck, where he was Senior Vice President Basic Research and Site Head, Rahway, Montreal and Madrid. He also chaired Merck’s Antibacterial and Antifungal Worldwide Business Strategy Team.
In 1999, Ismail joined as Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporation. Prior to his move to Industry, Ismail was Professor of Human Molecular Genetics, Monash University Medical School and Director of the Research Center for Functional Genomics and Human Disease. He was at Monash for 15 years.
He holds a Ph.D. in Medicine from the University of Cape Town, South Africa
He holds Adjunct Professorships of Medicine at Washington University, St Louis, Missouri, USA, and Monash University Medical School, Melbourne, Australia; a Foreign Adjunct Professorship at The Karolinska Institute, Stockholm, Sweden; and is a William Pitt Fellow at Pembroke College, Cambridge University, UK.
He is a member of the Board of Athersys Inc., Biotie Therapies, and Astex Pharmaceuticals.
“Forepont’s unique philosophy truly unlocks value by accompanying entrepreneurs through every step of their growth. I am proud to work along ambitious founders as well as with talented partners throughout their journey, especially within the French Ecosystem.”
Julien joined Forepont in late 2018 as General Partner in charge of Europe. He seats on the board of the French companies bringing is financial and managerial expertise. Julien is also developing key partnerships with French and European institutions focusing on sourcing opportunities and strategic development.
Julien stepped in as the CEO of BioSpeedia SAS following the investment Forepont and powered the startup to become one of the leaders in the European rapid diagnostic test sector generating over 12 million dollars revenues within the first 6 months. Julien drove a strategic reindustrialization in France and won a significant mandate from the French government during the COVID crisis.
In 2015, Julien transitioned into Venture Capital in Switzerland and France including a role as the Venture Partner for France & Switzerland at Joyance Partners – one of the most active Corporate VC funds in the Silicon Valley focusing on healthcare and nutrition, leading many investments for the fund.
In 2009, Julien joined AG2R La Mondiale as the Head of Alternative Investment investing more than 2 billion dollars in a variety of strategies and was named several times as top French Institutional Investors.
In 2006, Julien started his career in the Silicon Valley where he launched his 1st venture Dynamic Fund Management.
Julien holds an MBA from Columbia Business School (Dean’s List) and London Business School. He also graduated from AMSE in France with an engineering degree in statistics and from Saint Mary’s College of California with an MSc in Finance.
In 2010, Julien finished valedictorian of the Certified International Investment Analyst exam and is since a member of the French SFAF.
“Applying AI and ML to neurodegenerative diseases has led to exponential progress in a short period of time demonstrating how efficient Forepont’s driving force can impact science and technology in complicated fields.”
Larry has been with Forepont since 2015 and has been the driving force as the co-founder and CTO of BeCareLink. Together with medical authorities, he created and developed the revolutionary platform that uses Machine Learning techniques to assess patient neurologic functions and clinically significant changes.
Larry, first, worked at Bell Laboratories where he was the co-inventor of a new type of neural network technology.
He, later, founded OuterCurve Technologies Inc which was funded by three public companies.
Larry is, also, the co-founder of Woman’s healthcare venture for detecting breast cancer that is in its 16th year of operation.
Larry has a Master of Philosophy in Computer Science, a MS in Computer Science and a MS in Mathematics from New York University.
25 years experience
Bruce has been Forepont’s CFO since the launch of the company. Bruce also has an operating partner for the US portfolio companies (CFO).
In 2002, he co-founded a Commodity Trading Advisor specializing in commodities and currencies. As its CFO, he executed a strategic partnership with SG Asset Management, Inc.
Later on, Bruce founded his own firm to provide advice to clients in a broad array of industries on matters from tax issues, strategic planning, and mergers & acquisitions.
Bruce holds a BS in accounting from Brooklyn College, CUNY. He obtained his CPA certificate in 1991 and is a member of the AICPA and NYSSCPA.